Emyria (ASX:EMD) share price up 131% this month. Here's why

The Emyria Ltd (ASX: EMD) share price has been one of the best performers over the month, rising an astonishing 131%. We take a closer look.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Emyria Ltd (ASX: EMD) share price has been one of the best performers over the month. The share price has risen an astonishing 131%. Today alone, shares in the healthcare technology and services company are up 13% to 27 cents at the time of writing.

During the late afternoon trade, the company's shares were being picked up for 26.5 cents. This reflects an all-time high for the Emyria share price.

We take a closer look into what's moving its shares over the past few weeks.

What's the go with Emyria?

At the start of February, shares in the healthcare technology and services company were swapping hands for as little as 11 cents. However, a raft of positive announcements led investors to revaluate the company's prospect, sending the Emyria share price higher.

The first release was related to the company winning a digital health grant from the Western Australian government early this month. For this project, Emyria took the leadership role. This aimed to help boost the state's digital health infrastructure and capacity in dealing with major health concerns.

Following the digital health grant, the company announced last week that it added a second Melbourne clinic to its portfolio. The expanded presence comes after Emyria revealed that it has achieved record patient appointments in January 2021. In total, the company now has six locations across Australia gathering clinical data to improve the platform for patient care.

Quick take on Emyria

Emyria, formerly known as Emerald Clinics, operates a network of specialist medical clinics and purpose-built, remote patient monitoring technologies.

The company captures real-world clinical data. This is used to provide consultation letters, containing information on prescription, recommended dosage, and duration of cannabinoid-based medicines.

Emyria share price performance

As noted, the Emyria share price began the month at 11 cents but has surged following positive investor sentiment. The company's shares hit an all-time high today of 26.5 cents and could go higher based on its market capitalisation.

Emyria's current value stands at around $57 million according to its current share price. This represents an opportunity for explosive growth should the company continue to impress investors with its progress.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A group of people push and shove through the doors of a store, trying to beat the crowd.
Broker Notes

2 ASX shares highly recommended to buy: Experts

Are these two stocks the best buys on the ASX?

Read more »

Smiling couple sitting on a couch with laptops fist pump each other.
Broker Notes

These ASX 200 shares could rise 20% to 55%

Brokers have good things to say about these shares.

Read more »

Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
Dividend Investing

I'd buy 5,883 shares of this ASX stock to aim for $1,000 of annual passive income

I’d pick this stock for its strong dividend record.

Read more »

A player pounces on the ball in the scoring zone of the field.
Best Shares

4 ASX 300 shares that ripped 100% or more in 2025

The S&P/ASX 300 Index rose 7.17% and delivered a total return, including dividends, of 10.66% in 2025.

Read more »

A little girl is about to launch down the slide with a blue sky and white clouds in the sky behind her.
Broker Notes

BHP vs. Fortescue shares: Goldman Sachs says 1 will rip and 1 will dip

Top broker Goldman Sachs upgraded its 12-month share price forecasts for BHP and Fortescue shares this week.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Broker Notes

Brokers rate these 3 ASX shares as buys in January

These ASX shares have an exciting outlook according to experts.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Share Fallers

Why Australian Ethical, Northern Minerals, PLS, and Woodside shares are falling today

These shares are ending the week in the red. But why?

Read more »